Jennifer Brown, MD, PhD, expanded upon the results of her and her colleagues’ study of the hepatotoxic effects of idelalisib, particularly as frontline treatment of younger patients with chronic lymphocytic leukemia, which was presented at the 57th American Society of Hematology Annual Meeting & Exposition.
Related Items
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Last modified: July 22, 2021
